Ideaya Biosciences shares are trading higher after the company announced its interim Phase 2 trial data for Darovasertib in Neoadjuvant Uveal Melanoma and a successful FDA type C meeting on registrational trial design for regulatory approval.
Portfolio Pulse from Benzinga Newsdesk
Ideaya Biosciences shares rose following positive interim Phase 2 trial data for Darovasertib in Neoadjuvant Uveal Melanoma and a successful FDA type C meeting on trial design for regulatory approval.
September 23, 2024 | 1:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ideaya Biosciences shares increased due to positive interim Phase 2 trial results for Darovasertib in Neoadjuvant Uveal Melanoma and a successful FDA type C meeting on trial design for regulatory approval.
The positive interim Phase 2 trial data suggests potential efficacy of Darovasertib, which is a significant milestone for Ideaya Biosciences. Additionally, the successful FDA type C meeting indicates progress towards regulatory approval, boosting investor confidence and likely driving the stock price up.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100